HHS Secretary Kathleen Sebelius probably wishes she never left Kansas.
She’s got one department—the Office of the National Coordinator for HIT (ONC)—that’s passing out HITECH money faster than a street-hawker with peep show tix in order to hasten the dissemination of EHRs.
And she’s got this other department—the Food and Drug Administration—that wants to regulate the dang things because of safety concerns…an idea that, depending on how it’s implemented, would completely gum-up what ONC is trying to do.
The FDA currently has nothing to do with electronic health records. Yet, according to Jeffrey Shuren, who directs the FDA’s Center for Devices and Radiological Health, it’s received reports of 6 deaths and several dozen injuries associated with EHRs on-the-fritz in last 2 years alone.
The mishaps have included mixed-up patients, misplaced test results, missing medical information, and failure to display allergy information, among other things.
“Because these reports are purely voluntary, they may represent only the tip of the iceberg,” Shuren warned. “We believe that a framework of federal oversight of HIT needs to assure patient safety.”
Shuren should only know that any mad dash for EHR cash on the hospital side will overwhelm the legacy EHR vendors who have neither the manpower nor the platform/software flexibility to handle the ensuing flood of customization projects that would be required to accommodate workflows at each hospital...that’s more accidents waiting to happen.
In prepared testimony for an FDA hearing on the matter yesterday, Shuren suggested the FDA could pursue 3 possible regulatory strategies for EHRs:
- Require that EHR vendors register with the FDA, voluntarily report adverse events and fix problems when they arise (Let's call this “Post Market Surveillance Lite”)
- Same as above, but with mandatory adverse event reporting. Additional requirements can be added at the FDA’s discretion: e.g. vendors must show they have software QC systems in place (“Post Market Surveillance”)
- Classify EHRs as Medical Devices, which would make them subject to the same pre-market regulatory scrutiny as, say a defibrillator goes through. In this instance, EHR vendors must prove to the FDA that its product is safe and efficacious before it can go to market (“Pre Market Approval”)
What’s Going to Happen
If nothing else, the FDA’s hearings have called attention to the Feds’ obligation to assure EHRs are safe and effective. After all, they’re spending taxpayer dollars to hasten EHR dissemination via HITECH.
But since the Feds are indeed committed to The Great EHR Roll-Out, they need to select a regulatory strategy that doesn’t gum it up. That pretty much eliminates Pre Market Approval.
So the Feds are left with the first 2 options. They can take their pick, knowing that the first is toothless and subject to capture by EHR vendors, and the second will take one to 2 years before it’s underway.
But…the FDA?
Why in the world do we have one HHS department turning the safety of EHRs into a public concern at the same time another is trying to promote their dissemination? Assuming HITECH provisions give ONC proper leeway, the job of assuring safety and efficacy of EHRs should be given to ONC, not the FDA. Sebelius should tell ONC to get it done and call off the dogs over at Food and Drug. It’ll just work better.
To be fair, in January, ONC released an RFP to address “undesirable and potentially harmful unintended consequences” of EHRs. But the FDA didn’t even wait to see how that played out. Do these guys talk to each other?
Glenn Laffel, MD, PhD
Sr. VP Clinical Affairs, Practice Fusion
Friday, February 26, 2010
Should the FDA Regulate EHR Safety?
Author: Glenn Laffel, MD, PhD
| Posted at: 4:35 AM |
Filed Under:
EHR,
FDA,
ONCHIT,
Quality and safety
|
Subscribe to:
Post Comments (Atom)
3 comments:
Excellent post!
You folks are definitely a talented group of people that have come together to improve healthcare through the use of technology!
The EHR Guy
I am a pharmacist who used to work for Medco. It was fairly common to get calls from patients who got the wrong dose, or wrong dosage form, of a medication due to electronic prescription generation. Either the doctor or assistant would select the wrong medication, I assume from a pull down menu with similarly spelled meds, the doctor would sign it, and the patient would be out the money, unless the doctor reimbursed them for the mistake. There was usually nothing technically wrong with the prescription--and it was definitely legible!--so there was usually not prompt for the pharmacist to call for a clarification. It has caused much frustration for patients. So, technology solved the problem of poor physician handwriting, which commonly causes mistakes and wastes everybody's time clarifying, but has caused another problem. I'm glad I don't have to take those calls anymore.
Glenn --
It's an interesting issue. Multiple government agencies often assert jurisdiction over a particular product, or issue, or process, and we can then end up with not only burdensome but sometimes conflicting requirements.
Here, the FDA has been thinking about EHRs for at least a year, and in February articulated -- as you've laid out -- three possible approaches to regulating HIT, which FDA asserts falls within the definition of "device." Only one of the three approaches would include the more onerous premarket approval pathway, and it seems that the FDA is more than open to using one of the other two possible approaches -- which are certainly more palatable.
I checked out the testimony of Jeffrey Shuren, Director of FDA’s Center for Devices and Radiological Health at the 2/25 HITPol adoption/certification workgroup meeting, available at: http://j.mp/bb7Qgj (check out the transcript too; his remarks begin on page 50; see also his comments in response to a question beginning on page 57).
The ONC is looking at incorporating FDA requirements as part of the definition of Stage 2 Meaningful Use, and that creates the opening for Sebelius to step in and work to harmonize the work of two agencies within her secretariat.
Since FDA is at the table and seems prepared to exercise its discretion and not over-regulate in this sphere, I am encouraged that there can be use made of existing systems within government to capture and process incident reports. Shuren makes the point that reporting is only the tip of the iceberg. There needs to be a commitment to addressing issues identified through reporting, and also to increased transparency.
The point was made at the workgroup meeting that EHR license agreements constrain communications among providers about problems and potential improvements. It seems to me that the industry should be encouraging that sort of communication and opportunity for continuous improvement, rather than face more draconian governmental controls.
The safety issues, including the FDA-related points, will be working their way up the ONC food chain in the coming months, and it will be interesting to see which direction this heads in.
I invite you and your readers to be in touch if you would like to participate in this dialogue directly.
-- David
David Harlow
The Harlow Group LLC
http://HealthBlawg.com
Post a Comment